See the difference in real people.

  • A young woman before starting treatment with Seysara

    BEFORE

  • A young woman after 3 weeks of treatment with Seysara

    AFTER 3 WEEKS

  • A young woman after 12 weeks of treatment with Seysara

    AFTER 12 WEEKS

Actual clinical trial subject. Results may vary.
  • A young man before starting treatment with Seysara

    BEFORE

  • A young man after 3 weeks of treatment with Seysara

    AFTER 3 WEEKS

  • A young man after 12 weeks of treatment with Seysara

    AFTER 12 WEEKS

Actual clinical trial subject. Results may vary. LOAD MORE
img
  • A young man before starting treatment with Seysara

    BEFORE

  • A young man after 3 weeks of treatment with Seysara

    AFTER 3 WEEKS

  • A young man after 12 weeks of treatment with Seysara

    AFTER 12 WEEKS

Actual clinical trial subject. Results may vary.
  • A young woman before starting treatment with Seysara

    BEFORE

  • A young woman after 3 weeks of treatment with Seysara

    AFTER 3 WEEKS

  • A young woman after 12 weeks of treatment with Seysara

    AFTER 12 WEEKS

Actual clinical trial subject. Results may vary.
img
  • A young man before starting treatment with Seysara

    BEFORE

  • A young man after 3 weeks of treatment with Seysara

    AFTER 3 WEEKS

  • A young man after 12 weeks of treatment with Seysara

    AFTER 12 WEEKS

Actual clinical trial subject. Results may vary.
  • A young woman before starting treatment with Seysara

    BEFORE

  • A young woman after 3 weeks of treatment with Seysara

    AFTER 3 WEEKS

  • A young woman after 12 weeks of treatment with Seysara

    AFTER 12 WEEKS

Actual clinical trial subject. Results may vary.

SEYSARA was effective WITH A DEMONSTRATED SAFETY PROFILE

  • Greater reduction in inflammatory acne
    by Week 121,2

    Average decrease in number of
    inflammatory acne spots

    • 15.3

      for SEYSARA patients vs 10.2 for placebo
      patients

      STUDY 1

    • 15.5

      for SEYSARA patients vs 11.1 for placebo
      patients

      STUDY 2

  • Improvement in overall acne
    severity by Week 121,2

    Treatment success (clear or almost clear) at 12
    weeks

    • 21.9%

      of SEYSARA patients vs 10.5% of placebo
      patients

      STUDY 1

    • 22.6%

      of SEYSARA patients vs 15.3% of placebo
      patients

      STUDY 2

  • Generally well tolerated
    by patients1

    SEYSARA had low rates of side effects.2

    • 3.1%

      of SEYSARA patients
      had nausea (vs 2.0%
      of placebo patients).1
    • <1%

      of female SEYSARA patients had
      vaginal infection (0.8%)
      and vaginal yeast infection
      (0.6%).1

* SEYSARA was studied in two clinical trials, each lasting 12 weeks and involving 2,002 patients with moderate to severe acne.1-3 Patients were given a 60 mg, 100 mg, or 150 mg tablet of SEYSARA by mouth, once a day, depending on their weight.2 The effectiveness of SEYSARA was primarily scored at Week 12 by a decrease in the number of inflammatory acne spots and treatment success.1-3 Treatment was considered successful if patients recieved a score of clear or almost clear based on an investigator’s assessment of overall acne severity.2 The decrease in the number of inflammatory acne spots was also evaluated at Weeks 3, 6, and 9.1-3

References:

1.SEYSARA [package insert]. Exton, PA: Almirall, LLC, 2018.

2.Moore A, Green LJ, Bruce S, et al. Once-daily oral sarecycline 1.5 mg/kg/day is effective for moderate to severe acne vulgaris: results from two identically designed, phase 3, randomized, double-blind clinical trials. J Drugs Dermatol. 2018;17(9):987-996.

3.Data on file, Almirall, LLC. CSR SC1401 30JUN2017 and CSR 1402. 2017.